Kyverna Therapeutics, Inc. Common Stock (KYTX)

Kyverna Therapeutics (NASDAQ:KYTX) stock fell 7.3% on Thursday, trading at $8.22 with significantly reduced volume. Analyst sentiment is mixed, with some issuing "buy" ratings and others "sell," leading to an overall "Moderate Buy" consensus from MarketBeat. Despite the stock being below its average analyst target of $30.00, the clinical-stage biotech recently exceeded its quarterly EPS estimate and has seen new institutional investments from firms like BlackRock Inc. and AIGH Capital Management LLC.

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to miv-cel (Kyverna Therapeutics) for non-active secondary progressive multiple sclerosis (naSPMS). This designation was based on compelling Phase 1 clinical data showing robust CAR T-cell expansion and B-cell reconstitution. Miv-cel, an autologous CD19-targeting CAR T-cell therapy, is also being developed for stiff person syndrome and generalized myasthenia gravis, positioning it as a potentially transformative treatment for progressive MS.

Kyverna Therapeutics (NASDAQ:KYTX) shares rose 6.7% to $8.72 on Monday, despite lower-than-average trading volume. The clinical-stage biotech, which focuses on engineered regulatory T-cell therapies, remains unprofitable but exceeded quarterly EPS expectations. Analysts hold a "Moderate Buy" consensus with a target price significantly above its current trading price.

AIGH Capital Management LLC has acquired 2,795,797 shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX), valued at approximately $24.9 million, making it their 10th largest holding. Despite Kyverna beating its quarterly EPS estimates, analysts anticipate the clinical-stage biotech will remain unprofitable this year. While HC Wainwright maintains a "Buy" rating with a $25 price target, overall analyst sentiment for KYTX is mixed due to its development-stage status, regulatory dependence, and high volatility.

Walleye Capital LLC has acquired 245,587 new shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) during the second quarter, valuing the stake at approximately $2.19 million and representing 0.40% of the company. Despite beating Q2 earnings estimates, Kyverna Therapeutics, a clinical-stage biotech company focused on T-cell therapies for autoimmune diseases, continues to face significant losses and remains highly volatile, with analysts giving it a "Moderate Buy" consensus rating but mixed views on its future. Its investment case hinges on clinical and regulatory progress for its engineered T-cell therapies.